to Content
Header Image

Dr. Ingrid PABINGER-FASCHING Professorin, Klinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien


 Ingrid Pabinger-Fasching started her scientific and clinical career in 1982 at the Medical University Clinic of Vienna, with particular scientific focus on hereditary and acquired thrombosis risk factors (molecular and biochemical basis, aspects of diagnosis, clinical features and therapy), aspects of haemophilia treatment and acquired hemorrhagic diathesis, fundamentals and clinical relevance of coagulation abnormalities in patients with oncologic and haemato-oncologic diseases, clinical and immunologic characteristics of patients with immune-thrombocytopenia, and specific haemostaseologic problems in critically-ill patients. In 1982 and 1985 she stayed in the laboratory of Prof.Dr.R.M. Bertina in Leiden, the Netherlands for periods of several weeks for scientic research.
 Since 1990 she leads a scientific working group. Since 2004 she holds the position of Professor of Hemostaseology at the Medical University of Vienna, and since 2008 she is vice-director of the Division of Hematology and Hemostaseology in the Department of Medicine I.


Member of the board of the "Gesellschaft für Thrombose und Haemostaseforschung" (GTH), 1992-1999 und 2007-2011; 1992-1995 as Councillor, 1995-1999 as Vice-president, since 2007 as President
Chairperson of the Nomination Committee for the Board of the European Hematology Association (EHA), since 2006
Co-chairman of the Subcommittee on Protein C and S of the Scientific and Standardisation Committee (SSC) of the International Society of Thrombosis and Haemostasis (ISTH), 1987-1990
Member of the American Society of Hematology (ASH®) International Member Committee for a 4-year term), 2010-2013


Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):844S-886S.
Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009 Apr;41(4):450-4.
Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac A L, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study (CATS). J Clin Oncol. 2009 Sep 1;27(25):4124-9.
Reitter S, Sturn R, Horvath B, Freitag R, Male C, Muntean W, Streif W, Pabinger I, Mannhalter C; the Austrian Molecular Haemophilia Study Group. Spectrum of causative mutations in patients with haemophilia A in Austria. Thromb Haemost. 2010 Apr 29;104(1). [In print]


Member of the Ethics Committee of the Medical University of Vienna, 2000-2007
Member of the "Fachhochschulrat", nominated by the Federal Minister of Education, Science and Culture, 2003-2008
Upper Austrian Scientists' Award (Oberösterr. Landeskulturpreis) for outstanding achievements in the field of scientific research, 2009